Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity | BRKR Stock News

Author's Avatar
Jun 02, 2025
Article's Main Image
  • Bruker Corporation (BRKR, Financial) unveils the proteoElute nanoLC system, enhancing peptide sensitivity by up to 50%.
  • The new PepSep Advanced nLC columns improve chromatographic resolution and proteomics identifications.
  • Developments offer significant advancements for ultra-sensitive proteomics workflows.

Bruker Corporation (BRKR), at the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), launched the state-of-the-art proteoElute nanoLC system. This pioneering nanoflow liquid chromatography (LC) system is equipped with ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology. Such innovations promise enhanced robustness, sensitivity, and proteome coverage, crucial for ultra-sensitive proteomics workflows.

The proteoElute system is particularly suitable for single-cell proteomics and other complex biological analyses, thanks to its ability to handle limited or complicated samples reliably. It features an advanced TwinScape™ technology that provides real-time system monitoring, alerting users of potential issues and ensuring the integrity of valuable samples.

In conjunction with the proteoElute system, Bruker introduces the next-generation PepSep Advanced nLC columns. These columns are engineered to deliver sharper peaks and higher-resolution separations, offering approximately 20% improvements in peptide identifications and 10% in protein identifications. The columns, combined with CaptiveSpray Ionization emitters, enhance long-term performance and cost efficiency by allowing for easy emitter replacement.

Industry experts, like W. Hayes McDonald from Vanderbilt University, praise the system's remarkable robustness and the PepSep columns' ability to provide consistent chromatography, making them a valuable tool in proteomics workflows. This launch underscores Bruker's commitment to advancing scientific exploration and innovation within the post-genomic era.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.